One of the devastating effects of acute exposure to organophosphates, like nerve agents, is the induction of severe and prolonged status epilepticus (SE), which can cause death, or brain damage if death is prevented. Seizures after exposure are initiated by muscarinic receptor hyperstimulation-after inhibition of acetylcholinesterase by the organophosphorus agent and subsequent elevation of acetylcholine-but they are reinforced and sustained by glutamatergic hyperexcitation, which is the primary cause of brain damage. Diazepam is the FDA-approved anticonvulsant for the treatment of nerve agent-induced SE, and its replacement by midazolam is currently under consideration. However, clinical data derived from the treatment of SE of any etiology, as well as studies on the control of nerve agent-induced SE in animal models, have indicated that diazepam and midazolam control seizures only temporarily, their antiseizure efficacy is reduced as the latency of treatment from the onset of SE increases, and their neuroprotective efficacy is limited or absent. Here, we review data on the discovery of a novel anticonvulsant and neuroprotectant, LY293558, an AMPA/GluK1 receptor antagonist. Treatment of soman-exposed immature, young-adult, and aged rats with LY293558, terminates SE with limited recurrence of seizures, significantly protects from brain damage, and prevents long-term behavioral deficits, even when LY293558 is administered 1 h post-exposure. More beneficial effects and complete neuroprotection is obtained when LY293558 administration is combined with caramiphen, which antagonizes NMDA receptors. Further efficacy studies may bring the LY293558 + caramiphen combination therapy on the pathway to approval for human use. (J.P. Apland), maria.braga@usuhs.edu (M.F. Braga).
Introduction
The devastating effects of acute exposure to nerve agents and other organophosphorus compounds (OPs) are now widely known, not only from available scientific literature and historical accounts, but also, unfortunately, because we still witness them in our days. Acute exposure causes excessive salivation, lacrimation, rhinorrhea, bronchorrhea and bronchospasms, cardiorespiratory suppression, and eventual muscle paralysis, while, in the brain, prolonged and intense seizures (status epilepticus, SE) are induced. These effects are due to the excessive elevation of acetylcholine in the peripheral and the central nervous systems, which follows the inhibition of acetylcholinesterase (the enzyme that catalyzes the breakdown of acetylcholine) by the OP (Sirin et al., 2012) . The lives of exposed individuals may be saved by pharmacologically (atropine injection) counteracting the peripheral symptoms and preventing acute respiratory failure (Hulse et al., 2014) ; however, the OP-induced SE must also be controlled, as prolonged SE can lead to death, or cause significant brain damage along with longterm neurological, cognitive, and emotional deficits (Aroniadou-Anderjaska et al., 2016) . Seizure activity after OP exposure is initiated by hyperstimulation of muscarinic cholinergic receptors by the elevated acetylcholine, and it is subsequently strengthened and maintained by glutamatergic hyperexcitation (McDonough Jr and Shih, 1997) , which is mainly responsible for excitotoxic neuronal damage and death (Deshpande et al., 2014a; Shih et al., 2003) . Status epilepticus, regardless of its etiology, is commonly treated with diazepam and/or other benzodiazepines, therefore, the Food and Drug Administration (FDA) has approved diazepam also for the treatment of OP-induced SE. However, both clinical and animal research studies have indicated that treatment of SE with benzodiazepines is often inadequate, and in some https://doi.org/10.1016/j.nbd.2019.02.017 Received 6 September 2018; Received in revised form 23 January 2019; Accepted 20 February 2019 cases, inappropriate.
The limitations of benzodiazepines in the treatment of SE
During SE, there is excessive glutamatergic activity, which can be counteracted either by pharmacological suppression of the activity of certain types of glutamate receptors, or by enhancement of GABA A receptor-mediated inhibition. Benzodiazepines are positive allosteric modulators of GABA A receptors (Campo-Soria et al., 2006; Gielen et al., 2012; Olkkola and Ahonen, 2008) , and have been in use as first-line treatment for SE regardless of its etiology (Cherian and Thomas, 2009; Rogalski and Rogalski, 2015; Trinka and Kälviäinen, 2017) , for about half a century (Henriksen, 1998) . However, the antiseizure efficacy of benzodiazepines is reduced as the administration latency from the onset of SE increases, and, therefore, these drugs are recommended for early treatment (Cherian and Thomas, 2009; Trinka and Kälviäinen, 2017) . In addition, seizure suppression by benzodiazepines is transient, necessitating follow-up with other anticonvulsants or with repeated and higher benzodiazepine doses, risking respiratory depression (Appleton et al., 1995; Chamberlain et al., 2014; Singhi et al., 2002) . Moreover, a significant percentage of SE cases is refractory to benzodiazepines (Cherian and Thomas, 2009; Dubey et al., 2017; Trinka and Kälviäinen, 2017) .
In SE caused by exposure to nerve agents or other OPs, glutamatergic hyperactivity is induced by overstimulation of muscarinic cholinergic receptors, secondary to the inhibition of acetylcholinesterase by the OP and the elevation of ambient acetylcholine in the brain. Accordingly, antagonists of muscarinic receptors are effective in stopping OP-induced SE, but only if administered shortly after the exposure (Lallement et al., 1998; Shih et al., 1999; Skovira et al., 2010) , while at later stages, control of SE requires suppression of glutamatergic hyperactivity (McDonough Jr and Shih, 1997) . The involvement of muscarinic, rather than nicotinic receptors in OP-induced hyperexcitability has also been demonstrated in in vitro studies (Harrison et al., 2004; Kozhemyakin et al., 2010) . The mechanisms by which muscarinic receptor hyperstimulation enhances glutamate release and culminates in the generation of seizures remain to be delineated, but evidence suggests that they involve a net increase in spontaneous EPSCs, primarily via a presynaptic effect in the synapses onto granule cells in the hippocampus (Kozhemyakin et al., 2010) , or by an M 1 muscarinic receptormediated enhancement of the hyperpolarization-activated cation current, Ih, in the basolateral nucleus of the amygdala (BLA; Miller et al., 2017) . The muscarinic receptor-mediated enhancement of both AMPAand NMDA receptor-mediated synaptic transmission found in the CA1 hippocampal region (de Sevilla and Buño, 2010; de Sevilla et al., 2008) may also play a significant role in the amplification of glutamatergic activity by muscarinic receptor hyperstimulation.
Research on nerve agent-induced SE and effective anticonvulsant antidotes is performed under the FDA's animal rule, according to which, when human efficacy studies are not ethical or feasible, the FDA regulations open the pathway for drug approval based on research in animals. Research in rats exposed to the nerve agent soman has shown that diazepam must be administered promptly after seizure initiation, because its anticonvulsant efficacy decreases with the progression of SE Niquet et al., 2016; Todorovic et al., 2012) ; similar are the findings when diazepam is administered after induction of SE by pilocarpine (Goodkin et al., 2003; Jones et al., 2002; Walton and Treiman, 1991) , which triggers seizure activity by similar mechanisms as OPs do (excessive activation of muscarinic receptors). In addition, diazepam administration to rats exposed to soman terminates SE only temporarily. Thus, Shih et al. (1999) observed a return of seizures within a 6 h monitoring period, in 25% of the rats who received 9 mg/kg diazepam at 5 min after the onset of soman-induced seizures. Moreover, in rats receiving 10 mg/kg diazepam at 1 h or 2 h after soman exposure, prolonged seizures returned after a transient cessation of SE, resulting in a total duration of SE within 24 h post-exposure that was equal to or greater than the SE duration in the soman-exposed animals that did not receive anticonvulsant treatment (Apland et al., 2014) . Since brain damage after acute nerve agent exposure is caused primarily by the prolonged seizures (Shih et al., 2003; Prager et al., 2013) , the limited neuroprotective efficacy of diazepam (Apland et al., 2014 (Apland et al., , 2018b de Araujo Furtado et al., 2010; Langston et al., 2012 ) may be primarily due to the short-lasting control of seizures. However, in a study where SE induced by exposure to paraoxon was controlled by repeated administrations of diazepam at 1 h, 3 h, and 5 h after exposure, so as to prevent recurrence of seizures, long-term cognitive and depression-like deficits still developed (Deshpande et al., 2014b) , suggesting that mechanisms other than seizure recurrence may also be involved in the inefficacy of diazepam to protect against brain damage.
Midazolam is currently under consideration to replace diazepam, mainly because of its rapid absorption and onset of action, water solubility, and long shelf life (Reddy and Reddy, 2015) . However, like diazepam, midazolam provides little protection if administered at long latencies after exposure. Thus, midazolam protects against nerve agentinduced brain damage in adult or young-adult rats, if it is administered at the time of exposure (Chapman et al., 2015) , or at the onset of seizures (RamaRao et al., 2014) , or after 5 min of seizure activity (Gilat et al., 2005) , but if it is given 1 h after exposure, it does not prevent histological brain damage, despite its antiseizure efficacy and other beneficial effects (Chapman et al., 2015) . There are not enough animal data on the recurrence of seizures after the initial cessation by midazolam, but in children brought with SE to emergency and intensive care, treatment with midazolam was associated with more seizure recurrence and higher mortality in comparison with diazepam (Singhi et al., 2002) . It is important to note that attempting to enhance GA-BAergic inhibition by benzodiazepine administration in order to suppress seizures and prevent brain damage, may be even more problematic in the young age, when the GABAergic system is still immature, and GABA A receptor activation may produce depolarization (Ben-Ari et al., 2012a , 2012b Khazipov et al., 2015) , thus exacerbating rather than suppressing network hyperexcitability. Particular attention must be paid to the findings that midazolam administration to 7-day-old rat pups, worsened the brain injury produced by pilocarpine-induced SE (Torolira et al., 2017) . Thus, treatment of SE with benzodiazepines can be ineffective in adults, but early in life it may also be harmful.
Since the primary mechanism of benzodiazepine action is the facilitation of GABA A receptor activation, the limited antiseizure and neuroprotective efficacy of these compounds can be attributed to the internalization and downregulation of GABA A receptors, which occur during SE (Deeb et al., 2012; Goodkin et al., 2005; Naylor et al., 2005; Niquet et al., 2016) . Similarly, the recurrence of seizures after the initial cessation by benzodiazepine treatment, may relate to the reduced availability of GABA A receptors-which may be further exacerbated by benzodiazepine exposure (Uusi-Oukari and Korpi, 2010; Vinkers and Olivier, 2012)-as well as the relatively rapid clearance rate of these anticonvulsants (Ramsay et al., 1979; Reddy and Reddy, 2015) . In contrast to GABA A receptors, glutamate receptors are upregulated during prolonged seizure activity (Joshi et al., 2017; Naylor et al., 2013; Rajasekaran et al., 2013; Wasterlain et al., 2013) . Therefore, antagonizing directly the hyperactivity of the glutamatergic system, rather than attempting to enhance GABAergic activity, can be expected to be a more efficacious approach for terminating nerve agent-induced seizures and protecting from brain damage.
Glutamatergic hyperexcitation and the role of GluK1containing kainate receptors
While GABA A receptors are internalized and downregulated during SE, all three types of ionotropic glutamate receptors, AMPA, kainate, and NMDA receptors, are upregulated. Thus, within 1 h of SE, there is a significant increase of NMDA receptors on the cell surface in dentate granule cells and CA3 pyramidal cells of the rat hippocampus, V. Aroniadou-Anderjaska, et al. Neurobiology of Disease xxx (xxxx) xxxx particularly the receptors containing the GluN2B (also known as NR2B) subunit , which is the NMDA receptor subtype playing a prominent role in excitotoxicity (Liu et al., 2007; Martel et al., 2012; Vizi et al., 2013) . Similarly, there is an increased surface expression of the GluA1 subunit-containing AMPA receptors in CA1 pyramidal neurons during SE (Joshi et al., 2017; Rajasekaran et al., 2013) . Furthermore, as mentioned above in section 1, when SE is induced by OP exposure, activation of muscarinic receptors may contribute to the upregulation of NMDA and AMPA receptors (de Sevilla and Buño, 2010; de Sevilla et al., 2008) . Expression of the GluK1 kainate receptor subunit (formerly known as GluR5; see Collingridge et al., 2009; Jane et al., 2009 ) also increases in the hippocampus, after SE (Ullal et al., 2005) . Kainate receptors containing the GluK1 subunit (GluK1Rs) are not widely distributed throughout the brain, but are heavily expressed in certain brain areas (Bettler et al., 1990) . Their role in the regulation of neuronal excitability in different brain regions involves modulation of both glutamatergic (Aroniadou-Anderjaska et al., 2012; Gryder and Rogawski, 2003; Li and Rogawski, 1998; Vignes et al., 1998) and GA-BAergic (Braga et al., 2003; Cossart et al., 1998; Rodriguez-Moreno et al., 2000; Wondolowski and Frerking, 2009 ) synaptic transmission, via postsynaptic and/or presynaptic mechanisms.
In the hippocampus, the net effect of GluK1R activation is to promote hyperexcitability, since selective GluK1R antagonists have been shown to block hippocampal epileptiform activity in vitro and limbic seizures in vivo induced by electrical stimulation, or by the muscarinic agonist pilocarpine (Smolders et al., 2002) . In the amygdala, where the expression of GluK1Rs is exceptionally high (Bettler et al., 1990; Li et al., 2001; Braga et al., 2003) , GluK1Rs are present on postsynaptic sites of both principal cells (Gryder and Rogawski, 2003) and interneurons (Braga et al., 2003) of the BLA, as well as on the presynaptic terminals of both cell types, where they mediate facilitation of glutamate release (Aroniadou-Anderjaska et al., 2012) and either facilitation or inhibition of GABA release, depending on the concentration of the agonist (inhibition of GABA release at high agonist concentrations, see Braga et al., 2003) . The net effect of GluK1R activation in the BLA network is an increased excitation and excitability, as suggested by a greater enhancement of spontaneous EPSCs versus IPSCs, and the increased anxiety or induction of seizures when a GluK1R agonist is injected into the BLA (Aroniadou-Anderjaska et al., 2012). Thus, GluK1Rs play a pro-hyperexcitability role in the hippocampus and the amygdala, two brain regions that are highly seizurogenic (Aroniadou-Anderjaska et al., 2008; Pitkanen et al., 1998) and are significantly involved in nerve agent-induced SE. The latter is evident not only in the extensive damage both structures suffer by nerve agent-induced SE (Apland et al., 2010; Aroniadou-Anderjaska et al., 2009 ), but it is also suggested by the findings that a) seizures, after soman exposure, are not induced unless AChE decreases significantly specifically in the BLA (Prager et al., 2013) , and b) microinjection of nerve agents into different brain regions can elicit convulsions only when the nerve agent is injected into the BLA (McDonough Jr et al., 1987) , suggesting a central role of this amygdala nucleus in the initiation and propagation of seizures after acute nerve agent exposure. , and midazolam (MDZ) terminate promptly the initial SE induced by soman, but only LY293558 reduces the total duration of SE within 24 h post-exposure. Soman (1.2xLD50) was administered to young-adult, male rats. Atropine and HI-6 were given within 1 min after soman injection, and LY293558 (10 mg/kg), DZP (10 mg/kg), or MDZ (5 mg/kg) were injected intramuscularly 1 h after the exposure. Representative EEG traces at 40 min, 2 h and 9 h after soman injection are shown from a rat that did not receive anticonvulsant treatment (A), a rat that received DZP (B), a rat that received MDZ (C) and a rat that received LY293558 (D). Notice the persistence of low-amplitude epileptiform activity and the return of seizures in the DZP-or MDZ-treated rats, but not in the LY293558-treated rat. Electrode placement for the recordings is shown diagrammatically in E (1, left frontal; 2, right frontal; 3, left parietal; 4, right parietal; 5, cerebellar reference electrode). The group data in (F) show the duration of the initial SE in each group (*P < 0.05, when the DZP and MDZ groups are compared; ***P < 0.001 in comparison to the SOMAN group which did not receive anticonvulsant treatment), and the total duration of SE within the 24 h period after the exposure (**P < 0.01 comparing the LY293558-treated group with the SOMAN group, and ***P < 0.001 comparing the LY293558-treated group with the DZP or MDZ groups; ANOVA followed by Fisher's LSD test). Sample sizes are n = 4 for the SOMAN group, n = 8 for the SOMAN+LY293558 group, n = 6 for the SOMAN +DZP group, and n = 8 for the SOMAN+MDZ group.
The anticonvulsant and neuroprotectant efficacy of the AMPA/ GluK1R antagonist LY293558
To investigate whether antagonizing GluK1Rs can suppress seizures induced by nerve agents, first we induced epileptiform activity by soman application in in vitro brain slices, and examined whether it is suppressed by (S)-3-(2-carboxybenzyl)willardiine (UBP302), which is a specific GluK1R antagonist (More et al., 2004) . Interestingly, soman induced brief epileptiform spikes in the CA1 hippocampal area, while in the BLA, prolonged seizure-like discharges appeared after soman application, lasting up to 40 s, with relatively long inter-discharge intervals; epileptiform activity in both brain regions was suppressed by UBP302 ). We continued with in vivo experiments, and tested the antiseizure and neuroprotective efficacy of (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558; also known as Tezampanel) after exposure of rats to soman. LY293558 is highly selective for the subtype of kainate receptors that contain the GluK1 subunit, but it also antagonizes AMPA receptors (Bleakman et al., 1996; Jane et al., 2009) . We considered that the relatively broad spectrum of glutamate receptor antagonism offered by LY293558 (antagonism of both GluK1Rs and AMPA receptors) may increase antiseizure efficacy. Indeed, administration of LY293558 at either 20 min or 1 h (Figueiredo et al., 2011b) after soman exposure, stopped the initial SE and resulted in 100% survival rate. Fig. 1 shows the effect of LY293558 on SE induced by exposure of young-adult male rats to soman, in comparison to the antiseizure effects of midazolam and diazepam. The anticonvulsants were administered at 1 h after soman injection (seizure onset varies from 6 to 10 min after soman injection; see Miller et al., 2015) ; investigating anticonvulsant and neuroprotective efficacies at delayed time points of drug administration is particularly important in nerve agent research, because in a scenario of mass exposure, it may take some time before the victims are placed under medical care and monitoring. All 3 anticonvulsants terminated the initial SE in < 20 min, but strong seizures returned, particularly in the animals that received diazepam or midazolam, making the total duration of SE within 24 h post-exposure in the benzodiazepine-treated groups, no different from that in rats who did not receive anticonvulsant treatment (Fig. 1) .
The longer-lasting antiseizure efficacy of LY293558 compared to diazepam or midazolam is probably attributable to the different mechanisms by which these drugs act, but the pharmacokinetics of LY293558 may also play a role. It is also important to note that in contrast to the benzodiazepines which lose efficacy as SE progresses (see section 2), LY293558 remains equally effective in stopping the initial SE even if administered 3 h after SE onset. In addition, LY293558 very effectively suppresses seizures that recur at later time-points after the initial cessation of SE, and this is accompanied by an obvious beneficial effect in the overall well-being of the animal (quick behavioral recovery and minimal weight loss; Figueiredo et al., unpublished observations) .
The limited control of seizures by the benzodiazepines in comparison to LY293558 is reflected in the extent of neuroprotection. Thus, in contrast to LY293558 administration, which reduced neurodegeneration in a number of limbic and cortical structures, and prevented neuronal loss in the BLA and the hippocampus Figueiredo et al., 2011b) , none of these neuroprotective effects were seen when diazepam was administered for seizure control (Apland et al., 2014;  Fig. 2A, B, C) . Protection against neuropathology by LY293558 was translated into protection against pathophysiological alterations in the BLA and development of anxiety-like behavior , in contrast to the rats treated with diazepam, which developed increased anxiety (Apland et al., 2014;  Fig. 2D ). We have been studying pathology and pathophysiology in the BLA in parallel with tests of increased anxiety, because reduction of GABAergic interneurons and impaired spontaneous and evoked synaptic inhibition in the BLA, as it occurs after soman exposure (Figueiredo et al., 2011b; Prager et al., 2014a Prager et al., , 2014b , are likely to result in hyperexcitability of the BLA network, which is well known to be associated with increased anxiety (Aroniadou-Anderjaska et al., 2007 Pidoplichko et al., 2014; Sajdyk and Shekhar, 1997; Shekhar et al., 2003; Zhou et al., 2010) .
Efficacy of LY293558 against lethality and brain damage in 10month-old rats
A drug with good anticonvulsant and neuroprotective efficacy against nerve agent exposure in young-adult animals, is not necessarily equally effective in older and aged animals. Therefore, we tested the anticonvulsant and neuroprotective efficacy of LY293558 in 10-monthold male rats. It was not surprising that these older rats were significantly more sensitive to lethality by nerve agent exposure compared to young-adult rats ; aged humans and animals are more vulnerable to the lethal effects of SE, regardless of its cause (Blair et al., 2009; Shih et al., 1990; Towne, 2007; Wozniak et al., 1991) . Treatment with LY293558 did not yield 100% 24-h survival rate in the 10-month-old rats, but it increased it from 33% in the group that did not receive anticonvulsant treatment to 90% when LY293558 was injected 20 min after exposure and 78% when LY293558 was injected 60 min after exposure. An unexpected finding was that the 10-month old rats took a longer time to develop seizures after soman injection, in comparison to young-adult rats exposed to a similar dose of soman (1.2xLD50), and a lower percentage of the older rats developed seizures, suggesting a lower susceptibility to seizure induction by acute nerve agent exposure, despite the higher mortality rate (Fig. 3A) . Cox regression analysis showed that over time (up to 30 days post-exposure), the risk of death was reduced in the LY293558-treated rats by over 80%, whether the anticonvulsant was given at 20 min or at 60 min after soman exposure (Fig. 3B) . The low mortality in the LY293558treated groups was probably related to the prompt cessation of SE by LY293558 , and was accompanied by significant decreases in neurodegeneration in all limbic regions examined (Fig. 3C ).
Seizures do not return and full neuroprotection is achieved when LY293558 administration is combined with caramiphen
From the results we obtained after LY293558 treatment of somanexposed young-adult or 10-month-old rats, it is evident that LY293558 provides significant but not complete protection against neuropathology ( Figs. 2A and 3C ). This may have consequences in long-term. Preliminary results have suggested that if we examine neuropathology and pathophysiology in the BLA of LY293558-treated rats at 6 months after soman exposure, we start seeing a small but significant neuronal loss and reduction in inhibition, accompanied by evidence of increased anxiety. Since NMDA receptors are prominently involved in excitotoxicity and cell death (Fujikawa, 2015; Liu et al., 2007; Portera-Cailliau et al., 1997) , we investigated whether the residual damage after soman exposure and treatment with LY293558 can be eliminated by combining LY293558 administration with an NMDA receptor antagonist. For this purpose, we chose to use caramiphen, an M1 muscarinic receptor antagonist (Hudkins et al., 1993) with NMDA receptor antagonistic properties (Figueiredo et al., 2011a; Fletcher et al., 1995; Raveh et al., 1999; Thurgur and Church, 1998) , which has been shown previously to offer protection against nerve agent-induced seizures and neuropathology (Figueiredo et al., 2011a; Raveh et al., 2003 Raveh et al., , 2008 Raveh et al., , 2014 Schultz et al., 2012 Schultz et al., , 2014 . We found that when LY293558 administration is combined with caramiphen, the initial SE is terminated significantly faster than when LY293558 is given alone, seizures do not return during 72 h of monitoring (Fig. 4A) , there are no degenerating neurons anywhere in the brain (Fig. 4B) , and no body weight loss (Apland et al., 2018a) .
The synergistic antiseizure and neuroprotective effect seen when caramiphen was combined with LY293558 can probably be attributed V. Aroniadou-Anderjaska, et al. Neurobiology of Disease xxx (xxxx) xxxx in large part to the NMDA receptor antagonistic properties of caramiphen (Figueiredo et al., 2011a; Fletcher et al., 1995; Raveh et al., 1999; Thurgur and Church, 1998) , but other mechanisms, such as blockade of voltage-gated calcium channels Thurgur and Church, 1998) and voltage-gated sodium channels (Leung et al., 2015) , or enhancement of GABAergic inhibition (Figueiredo et al., 2011a; Thurgur and Church, 1998 ) may also be involved. In addition, since M1 muscarinic receptors appear to play a role in the intensity of nerve agent-induced SE for about 40 min postexposure (Miller et al., 2017) , the antimuscarinic properties of caramiphen may contribute to the faster cessation of SE, depending on the latency of administration from the time of exposure.
Fig. 2.
LY293558 but not diazepam (DZP) protects against neurodegeneration and neuronal loss. Data shown were obtained 7 days after exposure of young-adult male rats to soman. A: Irreversible neuronal degeneration, as determined by staining with Fluoro-Jade C, is prevented by LY293558, but not by DZP treatment. The panoramic Nissl-stained sections (left) show the areas where neurodegeneration was evaluated, representative photomicrographs of Fluoro-Jade C-stained sections from the amygdala (Amy), piriform cortex (Pir), entorhinal cortex (Ent), and the hippocampus are shown in the middle, and group data (Median and Interquartile Range) of neuropathology scores are shown on the right (**P < 0.01 compared to either the SOMAN group, which did not receive anticonvulsant treatment, or the SOMAN+DZP group). B: Neuronal loss in the BLA and the CA1 hippocampal area is prevented by LY293558, but not by DZP treatment. The panoramic Nissl-stained sections (left) show the areas where neuronal loss was assessed. The Nissl-stained sections in the middle (total magnification 630×; scale bar, 50 μm) are representative photomicrographs from the 4 groups, as shown. The bar graph (right) shows group data (***P < 0.001 compared to the control group which was not exposed to soman). C: Loss of GABAergic interneurons in the BLA is prevented by LY293558, but not by DZP treatment. Group data and representative photomicrographs of GAD-67 immuno-stained interneurons in the BLA are shown on the left total magnification is 630×; (**P < 0.01 compared to the control group not exposed to soman). D: Damage and loss of GABAergic interneurons in the soman-exposed groups that did not receive anticonvulsant treatment or received DZP was accompanied by increased anxiety, as suggested by the reduced time in the center of the open field and increased startle response amplitude. For more details, see Apland et al. (2013 and and Figueiredo et al. (2011b) . In this and subsequent figures, damage has been evaluated in the ventral hippocampus, because it displays significantly greater neurodegeneration in comparison to the dorsal region (Apland et al., 2010) .
Full protection against brain damage by LY293558 + caramiphen in young rats
Is the novel approach of antagonizing AMPA and GluK1Rs, with or without concomitant treatment with an NMDA receptor antagonist, also effective in nerve agent-exposed young rats? When LY293558 was tested in postnatal-day-21 (P21) rats exposed to soman, it was found that this compound, in addition to stopping promptly the initial SE, it prevented long-term reduction in amygdala and hippocampal volumes, as well as accompanying behavioral deficits (Miller et al., 2015) . In the Miller et al. (2015) study, we did not examine neurodegeneration in long-term, because at 24 h and 1 week after exposure, there were no degenerating neurons in any group, despite the reduced amygdala and hippocampal volumes found at 30 and 90 days post-exposure in the group that did not receive anticonvulsant treatment. Therefore, when we compared the antiseizure and neuroprotective efficacy of the combination of LY293558 and caramiphen with the efficacy of LY293558 administration alone, in P21 rats, we studied neurodegeneration at 30 days post-exposure, when the amygdala and hippocampal volumes were significantly reduced (Apland et al., 2018b) . The results from the neurodegeneration assessment can be seen in Fig. 5A , where we also compare with the neuroprotective efficacy of diazepam. At the 30-day post-exposure time point, degenerating neurons were present in all groups, except for the group that received both LY293558 and caramiphen, which did not display neurodegeneration in any of the limbic structures studied or anywhere in the brain, as inspection confirmed. LY293558 alone provided significant but not complete neuroprotection, while the beneficial effects of diazepam were limited, and totally absent in the hippocampus. Accordingly, reduction in amygdala and hippocampal volume was prevented only in the groups that received LY293558 alone or in combination with caramiphen (Apland et al., 2018b) . Considering that in adult rats, there is significant neurodegeneration at 24 h and 7 days after soman exposure (Figueiredo et al., 2011b; Prager et al., 2014a) , while in P21 rats, degenerating neurons Fig. 3 . Effects of LY293558 administration to 10month-old rats exposed to soman. A: Despite the higher mortality rate of 10-month-old ("aged") rats compared to young-adult rats exposed to 1.2xLD 50 of soman, aged rats appear to be less susceptible to developing SE after acute exposure to soman. The bar graph on the left shows the percentage of rats that developed SE in the two age groups, contrasted with the 24-h mortality rate in rats that develop SE and anticonvulsant treatment is not administered; both age groups received the same dose of atropine sulfate (2 mg/kg) and HI-6 (125 mg/kg). The bar graph on the right shows the latency to seizure onset, which was longer in the aged rats compared to the young-adult rats (*P < 0.05, and ***P < 0.001). B: Effects of LY293558 on long-term survival rate: Kaplan-Meier survival curve calculated for a period of 30 days for aged rats exposed to soman with no administration of anticonvulsant treatment (SOMAN group), and for animals that received LY293558 at 20 min or 60 min after soman injection (***P < 0.001 vs. SOMAN group, based on Cox regression). C: Effects of LY293558 on neuronal degeneration: Representative photomicrographs of Fluoro-Jade-C-stained sections are from different brain regions of a rat from the SOMAN group, a rat treated with LY293558 at 20 min, and a rat treated with LY293558 at 60 after soman injection; neurodegeneration was assessed 1 day after soman exposure. Total magnification is 100×. Scale bar is 50 μm. The brain regions are: amygdala (AMY), hippocampal areas (CA1, CA3 and HILUS), piriform cortex (PIR), and entorhinal cortex (ENT). Group data (Median and Interquartile Range) of neuropathology scores are shown in the bar graph (*P < 0.05, in comparison to the SOMAN group). For more details, see Apland et al. (2017) .
were found at 30 days (Apland et al., 2018b) but not at 24 h and 7 days post-exposure (Miller et al., 2015) , future investigations should examine possible age-dependent differences in the time course of brain damage by nerve agents; in this regard, there is already evidence for the progressive nature of neuropathology in the young age, after pilocarpine-induced SE (Kubová and Mareš, 2013; van der Hel et al., 2014) .
Neuropathological damage produces pathophysiological changes. In the BLA of control rats, principal/pyramidal neurons generate synchronous "bursts" of GABA A receptor-mediated activity, in an oscillatory fashion, at an average frequency of 0.5 Hz (Aroniadou-Anderjaska et al., 2018) . Because synchronous, rhythmic inhibition is a fundamental mechanism underlying the generation of brain oscillations (Allen and Monyer, 2015; Sohal et al., 2009; Stark et al., 2013) , the inhibitory bursts in the BLA may play an important role in the oscillatory activity patterns generated by the BLA network, which appear to be associated with cognitive/emotional functions such as the perception of safety Stujenske et al., 2014) and the expression of fear (Karalis et al., 2016) . Thirty days after exposure of P21 rats to soman, the inhibitory bursts are absent in the group treated with caramiphen only, or with diazepam, while they are present in the groups treated with LY2935558 alone, or in combination with caramiphen (Fig. 5B ). The pathophysiological alterations in the BLA were accompanied by corresponding increases in anxiety (decreased time spent in the center of the open field and increased startle response amplitude), present only in the groups treated with caramiphen alone, or with DZP ( Fig. 5C ).
Concluding remarks
Nerve agents are deadly chemical weapons that continue to present a serious threat to military and civilian populations. Currently FDAapproved medical countermeasures are inadequate in counteracting nerve agent-induced SE and preventing brain damage, which leads to long-term neurological and psychiatric disorders. Our data suggest that because the brain damage caused by acute nerve exposure is longlasting, and resulting neurological and behavioral deficits may not appear until long after the exposure, neuroprotective efficacy studies in animals must extend to long post-exposure time points.
When diazepam or midazolam is included in combination therapies to counteract nerve agent-induced SE, either drug can provide beneficial effects (Koplovitz et al., 2001; Niquet et al., 2017a and 2017b) , but the evidence is clear that, used alone, neither benzodiazepine has satisfactory antiseizure or neuroprotective efficacy. We have discovered that LY293558 (Tezampanel), an antagonist of AMPA and GluK1 receptors, is very effective against nerve agent-induced seizures and neuropathology, even when administered at delayed time points after Fig. 4 . Administration of LY293558 + caramiphen (CRM) terminates soman-induced SE faster than LY293558 alone, with virtually no return of seizures, and fully protects against neuronal degeneration. Young-adult male rats were exposed to 1.2xLD 50 soman. At 20 min after soman injection they were administered atropine and HI-6 but no anticonvulsant (SOMAN group), or were also injected with 15 mg/kg LY293558, or with LY293558 (15 mg/kg) along with CRM (50 mg/kg). A: LY293558 administered along with CRM, terminated the initial SE faster than LY293558 alone, and, therefore, the duration of the initial SE was shorter in the LY293558 + CRM group (left set of bars). There was virtually no return of seizures in the LY293558 + CRM group, making the total duration of SE in the 24-h (middle set of bars) or 72-h (right set of bars) post-exposure period significantly shorter in the LY293558 + CRM group compared to the group that received only LY293558 (***P < 0.001 compared to the SOMAN group; # P < 0.05 and ## P < 0.01, ### P < 0.001 for the comparisons between the LY293558 alone and the LY293558 + CRM groups). B: Panoramic photomicrographs of Nissl-stained sections showing the brain regions where neuronal degeneration was assessed are shown on the top left. The right panel shows representative photomicrographs of Fluoro-Jade-C-stained sections from different brain regions of a rat from the SOMAN group, a rat from the SOMAN+LY293558 group, and a rat from the SOMAN+LY293558 + CRM group, 7 days after soman exposure. Total magnification is 100×. Scale bar is 50 μm. The brain regions are: amygdala (Amy), piriform cortex (Pir), neocortical region (Neo-Ctx), hippocampal areas (CA1, CA3, and HILUS), and entorhinal cortex (Ent). The bar graph depicts neuropathology scores (Median and Interquartile Range) for the three groups. **P < 0.01 and ***P < 0.001 in comparison to the SOMAN group. # P < 0.05 when the SOMAN+LY293558 + CRM group is compared with the SOMAN+LY293558 group. For details, see Apland et al. (2018a) .
V. Aroniadou-Anderjaska, et al. Neurobiology of Disease xxx (xxxx) xxxx Fig. 5 . In P21 rats exposed to soman, diazepam (DZP) offers only minimal protection against brain damage, while the LY293558 + caramiphen (CRM) combination treatment provides full protection against neuronal degeneration, pathophysiological alterations in the BLA, and behavioral deficits. Data were obtained 30 days after exposure to 1.2xLD50 soman (anticonvulsants were administered 1 h after soman injection). A: The Nissl-stained section on the left shows the brain regions where neurodegeneration was assessed. Representative photomicrographs of Fluoro-Jade-C-stained sections are shown on the right (total magnification is 100×; scale bar, 50 μm), from the amygdala (Amy), piriform cortex (Pir), and hippocampal regions, along with the group data of the neuropathology scores (median and interquartile range) for the LY293558 (15 mg/kg), DZP (10 mg/kg), CRM (50 mg/kg), and LY293558 + CRM-treated groups (*P < 0.05, **P < 0.01, ***P < 0.001). B: Wholecell recordings of background inhibitory activity (spontaneous IPSCs) from principal BLA neurons (+30 mV holding potential). In rats treated with DZP or CRM, spontaneous bursts of summated IPSCs were not present in any of the recorded neurons. The top "control" trace is representative from rats not exposed to soman. Bar graph shows group data of the total charge transferred by spontaneous IPSCs (during a 10 s time window; *P < 0.05, **P < 0.01). C: Increased anxiety developed only in the groups treated with DZP or CRM. The two panels on the left show the time spent in the center of the open field and the total distance travelled. The right panel shows the amplitude of the startle responses to acoustic stimuli at two different sound intensities (*P < 0.05, **P < 0.01). "Control", white (open) bar in B and C represent data from rats that were not exposed to soman. For details, see Apland et al. (2018b) .
the exposure. LY293558 has been tested clinically, as an analgesic, and has been proven to be safe and well-tolerated (Gilron et al., 2000; Sang et al., 2004) . Our extensive pre-clinical studies demonstrating the effectiveness of LY293558 against nerve agents have led to the formation of a new company (Proniras) to further develop LY293558 as a new countermeasure. On April 25, 2018, it was announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a $89.5 million contract to Proniras for advanced research and development of LY293558, for the treatment of nerve agent inducedseizures that are refractory to benzodiazepines. These further studies are likely to result in the availability of a novel, safe and effective therapeutic against nerve agent-induced seizures and brain damage that will enhance our treatment response capabilities during an emergency.
Our more recent findings of faster cessation of SE, absence of recurrent seizures, and complete neuroprotection when LY293558 is administered along with caramiphen, must receive attention, particularly for the protection of the population that is more sensitive to lethality and long-term morbidity (infant and aged humans). The NMDA receptor antagonistic properties of caramiphen can be expected to be even more crucial for full neuroprotection to be achieved in very young animals, because NMDA receptor activity is exceptionally high in the young age (Johnston, 1994) . Caramiphen is not a new drug. It was approved by the FDA in 1973 as an over-the-counter antitussive for human use from the age of 2 years and above; FDA approval was withdrawn in 1984 due to the inefficacy of the drug as an antitussive, but not because of safety concerns. Certainly, however, efficacy and safety studies, at different doses and administration protocols, are necessary before the LY293558 + CRM combination treatment can be on the pathway to approval for human use.
